Online inquiry

IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10780MR)

This product GTTS-WQ10780MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FGFR4 gene. The antibody can be applied in Non-alcoholic steatohepatitis (NASH) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001291980.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2264
UniProt ID P22455
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10780MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10092MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ9322MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMP-321
GTTS-WQ8470MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HTI-1088
GTTS-WQ2436MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 157
GTTS-WQ9910MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ15544MR IVTScrip™ mRNA-Anti-NGcGM3, UNII-52G405U1E5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UNII-52G405U1E5
GTTS-WQ4637MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986016
GTTS-WQ7315MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FPA-144
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW